HALT PROGRESSION OF POLYCYSTIC KIDNEY DISEASE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究有两个方面，研究A的目的是确定肾功能(GFR和GT；60ml/min/1.73m2)和正常高血压或高血压的ADPKD受试者，ACE-I/ARB联合治疗和低血压与受体阻滞剂和普通血压是否随着时间的推移减少肾脏体积增加的百分比。B研究的目的是确定中度肾功能不全(GFR 30-60ml/min/1.73m2)的ADPKD患者，与ACE-I相比，ACE-I/ARB联合治疗，在标准血压控制(？130/85 mm Hg)的情况下，加上额外的降压药，是否会增加血清肌酐增加一倍的时间，ESRD或死亡。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study has two arms, the aim in study A is to determine whether ADPKD subjects with preserved renal function (GFR >60 ml/min/1.73m2) and high-normal blood pressure or hypertension, ACE-I/ARB combination therapy and low blood pressure vs ¿-blocker and usual blood pressure reduces the percent increase in kidney volume over time. The aim in study B is to determine whether ADPKD subjects with moderate renal insufficiency (GFR 30-60 ml/min/1.73m2), ACE-I/ARB combination therapy as compared to ACE-I, with additional antihypertensive agents at standard blood pressure control (?130/85 mm Hg), increases the time to doubling of serum creatinine, ESRD or death.